Quantitative imaging reveals heterogeneous growth dynamics and treatment-dependent residual tumor distributions in a three-dimensional ovarian cancer model.

Three-dimensional tumor models have emerged as valuable in vitro research tools, though the power of such systems as quantitative reporters of tumor growth and treatment response has not been adequately explored. We introduce an approach combining a 3-D model of disseminated ovarian cancer with high-throughput processing of image data for quantification of growth characteristics and cytotoxic response. We developed custom MATLAB routines to analyze longitudinally acquired dark-field microscopy images containing thousands of 3-D nodules. These data reveal a reproducible bimodal log-normal size distribution. Growth behavior is driven by migration and assembly, causing an exponential decay in spatial density concomitant with increasing mean size. At day 10, cultures are treated with either carboplatin or photodynamic therapy (PDT). We quantify size-dependent cytotoxic response for each treatment on a nodule by nodule basis using automated segmentation combined with ratiometric batch-processing of calcein and ethidium bromide fluorescence intensity data (indicating live and dead cells, respectively). Both treatments reduce viability, though carboplatin leaves micronodules largely structurally intact with a size distribution similar to untreated cultures. In contrast, PDT treatment disrupts micronodular structure, causing punctate regions of toxicity, shifting the distribution toward smaller sizes, and potentially increasing vulnerability to subsequent chemotherapeutic treatment.

[1]  Genee Y. Lee,et al.  Three-dimensional culture models of normal and malignant breast epithelial cells , 2007, Nature Methods.

[2]  M. Bissell,et al.  ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini , 2001, Nature Cell Biology.

[3]  Timothy Zhu,et al.  A Phase II Trial of Intraperitoneal Photodynamic Therapy for Patients with Peritoneal Carcinomatosis and Sarcomatosis , 2006, Clinical Cancer Research.

[4]  B. Pogue,et al.  Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. , 2005, Journal of the National Cancer Institute.

[5]  T. Delaney,et al.  Photodynamic therapy of cancer. , 1988, Comprehensive therapy.

[6]  Mina J. Bissell,et al.  Putting tumours in context , 2001, Nature Reviews Cancer.

[7]  Jayanta Debnath,et al.  The Role of Apoptosis in Creating and Maintaining Luminal Space within Normal and Oncogene-Expressing Mammary Acini , 2002, Cell.

[8]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[9]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[10]  Bryan Q. Spring,et al.  In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring , 2009, British Journal of Cancer.

[11]  Jayanta Debnath,et al.  Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.

[12]  I. Jacobs,et al.  Three‐dimensional in vitro cell biology models of ovarian and endometrial cancer , 2009, Cell proliferation.

[13]  K. Bury Log-Normal Distributions , 1999 .

[14]  W. Stahel,et al.  Log-normal Distributions across the Sciences: Keys and Clues , 2001 .

[15]  I. Jacobs,et al.  In vitro three‐dimensional modelling of human ovarian surface epithelial cells , 2009, Cell proliferation.

[16]  K. Fujiwara Can carboplatin replace cisplatin for intraperitoneal use? , 2008, International Journal of Gynecologic Cancer.

[17]  M. Markman Pharmaceutical Management of Ovarian Cancer , 2012, Drugs.

[18]  Tayyaba Hasan,et al.  In vitro ovarian tumor growth and treatment response dynamics visualized with time-lapse OCT imaging. , 2009, Optics express.

[19]  Timothy Zhu,et al.  Phase II Trial of Debulking Surgery and Photodynamic Therapy for Disseminated Intraperitoneal Tumors , 2001, Annals of Surgical Oncology.

[20]  M G Nichols,et al.  Fluence rate effects in photodynamic therapy of multicell tumor spheroids. , 1993, Cancer research.

[21]  T. Foster,et al.  ALA- and ALA-hexylester-induced protoporphyrin IX fluorescence and distribution in multicell tumour spheroids , 2001, British Journal of Cancer.

[22]  Michael R Hamblin,et al.  Intraperitoneal photoimmunotherapy of ovarian carcinoma xenografts in nude mice using charged photoimmunoconjugates. , 2000, Gynecologic oncology.

[23]  Jayanta Debnath,et al.  Modelling glandular epithelial cancers in three-dimensional cultures , 2005, Nature Reviews Cancer.

[24]  V. Weaver,et al.  Tissue structure, nuclear organization, and gene expression in normal and malignant breast. , 1999, Cancer research.

[25]  T. Foster,et al.  Effects of the Subcellular Redistribution of Two Nile Blue Derivatives on Photodynamic Oxygen Consumption , 1998, Photochemistry and photobiology.

[26]  C. Arteaga,et al.  Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. , 1998, Experimental cell research.

[27]  G. Laurie,et al.  Basement membrane complexes with biological activity. , 1986, Biochemistry.

[28]  Jarod C Finlay,et al.  Photobleaching kinetics of Photofrin in vivo and in multicell tumour spheroids indicate two simultaneous bleaching mechanisms. , 2004, Physics in medicine and biology.

[29]  Michael R Hamblin,et al.  Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. , 1996, Cancer research.